

Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/VADAC2E4CF8EEN.html>

Date: October 2022

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: VADAC2E4CF8EEN

Abstracts

Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.

Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 7, 22, 8 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and

molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Vaginal Cancer - Overview
Vaginal Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vaginal Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vaginal Cancer - Companies Involved in Therapeutics Development
AstraZeneca Plc
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
Bristol-Myers Squibb Co
Chengdu Institute of Biological Products Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Hookipa Pharma Inc
ISA Pharmaceuticals BV
Merck & Co Inc
Merck KGaA
Ology Bioservices Inc
Ono Pharmaceutical Co Ltd
PDS Biotechnology Corp
Perseus Proteomics Inc
Pionyr Immunotherapeutics Inc
Precigen Inc
Privo Technologies Inc
RemeGen Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Zerun Biotechnology Co Ltd
SinoCelltech Group Ltd
SQZ Biotechnologies Co

Suzhou Neupharma Co Ltd

Transcenta Holding Ltd

Transgene SA

Turnstone Biologics Inc

Vaginal Cancer - Drug Profiles

adavosertib - Drug Profile

Product Description

Mechanism Of Action

bevacizumab - Drug Profile

Product Description

Mechanism Of Action

bintrafusp alfa - Drug Profile

Product Description

Mechanism Of Action

cisplatin - Drug Profile

Product Description

Mechanism Of Action

decitabine - Drug Profile

Product Description

Mechanism Of Action

disitamab vedotin - Drug Profile

Product Description

Mechanism Of Action

durvalumab - Drug Profile

Product Description

Mechanism Of Action

durvalumab + tremelimumab - Drug Profile

Product Description

Mechanism Of Action

HB-201 - Drug Profile

Product Description

Mechanism Of Action

HB-202 - Drug Profile

Product Description

Mechanism Of Action

HPV-16 E7 - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus (9 valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 16, 18, 58] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

M-9241 - Drug Profile

Product Description

Mechanism Of Action

MEDI-0457 - Drug Profile

Product Description

Mechanism Of Action

nivolumab - Drug Profile

Product Description

Mechanism Of Action

NTO-1151 - Drug Profile

Product Description

Mechanism Of Action

Oncolytic Virus to Target E6 and E7 for Human Papillomavirus (HPV) Associated Solid

Tumors - Drug Profile
Product Description
Mechanism Of Action
PDS-0101 - Drug Profile
Product Description
Mechanism Of Action
peltopepimut-s - Drug Profile
Product Description
Mechanism Of Action
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
PPMX-T002 - Drug Profile
Product Description
Mechanism Of Action
PRGN-2009 - Drug Profile
Product Description
Mechanism Of Action
PRV-211 - Drug Profile
Product Description
Mechanism Of Action
PY-159 - Drug Profile
Product Description
Mechanism Of Action
PY-314 - Drug Profile
Product Description
Mechanism Of Action
RX-208 - Drug Profile
Product Description
Mechanism Of Action
SCT-1000 - Drug Profile
Product Description
Mechanism Of Action
SQZ-AACs (Oncology) - Drug Profile
Product Description
Mechanism Of Action
SQZ-APCs (Oncology) - Drug Profile
Product Description
Mechanism Of Action

tipapkinogene sovacivec - Drug Profile

Product Description

Mechanism Of Action

TST-005 - Drug Profile

Product Description

Mechanism Of Action

Vaginal Cancer - Dormant Projects

Vaginal Cancer - Product Development Milestones

Featured News & Press Releases

Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers

Jun 17, 2015: GARDASIL9: New HPV vaccine approved in the European Union

Apr 01, 2015: Merck's HPV Vaccine, GARDASIL 9, now available in Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Vaginal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Vaginal Cancer - Pipeline by AstraZeneca Plc, 2022
Vaginal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Vaginal Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
Vaginal Cancer - Pipeline by Eisai Co Ltd, 2022
Vaginal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Vaginal Cancer - Pipeline by Gilead Sciences Inc, 2022
Vaginal Cancer - Pipeline by Hookipa Pharma Inc, 2022
Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022
Vaginal Cancer - Pipeline by Merck & Co Inc, 2022
Vaginal Cancer - Pipeline by Merck KGaA, 2022
Vaginal Cancer - Pipeline by Ology Bioservices Inc, 2022
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Vaginal Cancer - Pipeline by PDS Biotechnology Corp, 2022
Vaginal Cancer - Pipeline by Perseus Proteomics Inc, 2022
Vaginal Cancer - Pipeline by Pionyr Immunotherapeutics Inc, 2022
Vaginal Cancer - Pipeline by Precigen Inc, 2022
Vaginal Cancer - Pipeline by Privo Technologies Inc, 2022
Vaginal Cancer - Pipeline by RemeGen Co Ltd, 2022
Vaginal Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
Vaginal Cancer - Pipeline by SinoCelltech Group Ltd, 2022
Vaginal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
Vaginal Cancer - Pipeline by Suzhou Neupharma Co Ltd, 2022

Vaginal Cancer - Pipeline by Transcenta Holding Ltd, 2022

Vaginal Cancer - Pipeline by Transgene SA, 2022

Vaginal Cancer - Pipeline by Turnstone Biologics Inc, 2022

Vaginal Cancer - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vaginal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/VADAC2E4CF8EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VADAC2E4CF8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

